Novo Nordisk | NVO - Cash And Equivalent

Stock Price
37.08
Daily Change
-0.40 -1.07%
Monthly
-21.81%
Yearly
-52.89%
Q1 Forecast
35.99

Novo Nordisk reported DKK38.94B in Cash and Equivalent for its fiscal quarter ending in March of 2025.





Cash And Equivalent Change Date
ANI Pharmaceuticals USD 285.58M 22.98M Dec/2025
Aurora Cannabis CAD 56.36M 39.33M Dec/2025
Bausch Health Companies USD 1.31B 419M Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Canopy Growth CAD 298.06M 171.86M Sep/2025
Corcept Therapeutics USD 120.49M 4.64M Dec/2025
Drreddys Laboratories INR 18.66B 9.65B Dec/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Novo Nordisk DKK 38.94B 24.15B Mar/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Pacira USD 158.54M 10.96M Dec/2025
Perrigo USD 432.1M 22.1M Sep/2025
Phibro Animal Health USD 55.49M 17.28M Dec/2025
Prestige Brands USD 62.37M 56.73M Dec/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025
Zoetis USD 2.08B 649M Sep/2025